264 related articles for article (PubMed ID: 16440324)
1. Role of osteoblast suppression in multiple myeloma.
Stewart JP; Shaughnessy JD
J Cell Biochem; 2006 May; 98(1):1-13. PubMed ID: 16440324
[TBL] [Abstract][Full Text] [Related]
2. Osteoblast function in myeloma.
Roodman GD
Bone; 2011 Jan; 48(1):135-40. PubMed ID: 20601285
[TBL] [Abstract][Full Text] [Related]
3. [Mechanisms for formation of myeloma bone disease].
Yata K; Abe M; Matsumoto T
Clin Calcium; 2008 Apr; 18(4):438-46. PubMed ID: 18379024
[TBL] [Abstract][Full Text] [Related]
4. TGF-β-related mechanisms of bone destruction in multiple myeloma.
Matsumoto T; Abe M
Bone; 2011 Jan; 48(1):129-34. PubMed ID: 20570621
[TBL] [Abstract][Full Text] [Related]
5. Bone-resorbing cells in multiple myeloma: osteoclasts, myeloma cell polykaryons, or both?
Silvestris F; Ciavarella S; De Matteo M; Tucci M; Dammacco F
Oncologist; 2009 Mar; 14(3):264-75. PubMed ID: 19286760
[TBL] [Abstract][Full Text] [Related]
6. Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells.
Silvestris F; Cafforio P; Calvani N; Dammacco F
Br J Haematol; 2004 Aug; 126(4):475-86. PubMed ID: 15287939
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of myeloma bone disease.
Roodman GD
J Cell Biochem; 2010 Feb; 109(2):283-91. PubMed ID: 20014067
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
[TBL] [Abstract][Full Text] [Related]
9. Negative regulation of the osteoblast function in multiple myeloma through the repressor gene E4BP4 activated by malignant plasma cells.
Silvestris F; Cafforio P; De Matteo M; Calvani N; Frassanito MA; Dammacco F
Clin Cancer Res; 2008 Oct; 14(19):6081-91. PubMed ID: 18829486
[TBL] [Abstract][Full Text] [Related]
10. Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets.
Giuliani N; Mangoni M; Rizzoli V
Exp Hematol; 2009 Aug; 37(8):879-86. PubMed ID: 19446662
[TBL] [Abstract][Full Text] [Related]
11. The osteoblastic niche in the context of multiple myeloma.
Toscani D; Bolzoni M; Accardi F; Aversa F; Giuliani N
Ann N Y Acad Sci; 2015 Jan; 1335():45-62. PubMed ID: 25424768
[TBL] [Abstract][Full Text] [Related]
12. 17beta-Estradiol overcomes human myeloma RPMI8226 cell suppression of growth, ALP activity, and mineralization in rat osteoblasts and improves RANKL/OPG balance in vitro.
Li Q; Yu K; Tian X; Kong F; You Y; Chen Z; Zou P
Leuk Res; 2009 Sep; 33(9):1266-71. PubMed ID: 19167063
[TBL] [Abstract][Full Text] [Related]
13. [Bone disease in multiple myeloma and its mechanism].
Abe M
Clin Calcium; 2006 Apr; 16(4):565- 71. PubMed ID: 16582506
[TBL] [Abstract][Full Text] [Related]
14. Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK.
Hecht M; Heider U; Kaiser M; von Metzler I; Sterz J; Sezer O
Br J Haematol; 2007 Aug; 138(4):446-58. PubMed ID: 17593251
[TBL] [Abstract][Full Text] [Related]
15. [Neurologic sequelae of bone changes in multiple myeloma and its therapy].
Basić-kes V; Basić-Jukić N; Kes P; Demarin V; Labar B
Acta Med Croatica; 2002; 56(3):103-7. PubMed ID: 12630341
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiology of multiple myeloma bone disease.
Lentzsch S; Ehrlich LA; Roodman GD
Hematol Oncol Clin North Am; 2007 Dec; 21(6):1035-49, viii. PubMed ID: 17996587
[TBL] [Abstract][Full Text] [Related]
17. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease.
Heider U; Hofbauer LC; Zavrski I; Kaiser M; Jakob C; Sezer O
Biochem Biophys Res Commun; 2005 Dec; 338(2):687-93. PubMed ID: 16216218
[TBL] [Abstract][Full Text] [Related]
18. Sclerostin is overexpressed by plasma cells from multiple myeloma patients.
Brunetti G; Oranger A; Mori G; Specchia G; Rinaldi E; Curci P; Zallone A; Rizzi R; Grano M; Colucci S
Ann N Y Acad Sci; 2011 Nov; 1237():19-23. PubMed ID: 22082361
[TBL] [Abstract][Full Text] [Related]
19. Myeloma and bone disease: "the dangerous tango".
Epstein J; Walker R
Clin Adv Hematol Oncol; 2006 Apr; 4(4):300-6. PubMed ID: 16728940
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo.
Chantry AD; Heath D; Mulivor AW; Pearsall S; Baud'huin M; Coulton L; Evans H; Abdul N; Werner ED; Bouxsein ML; Key ML; Seehra J; Arnett TR; Vanderkerken K; Croucher P
J Bone Miner Res; 2010 Dec; 25(12):2633-46. PubMed ID: 20533325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
